• Chi-Shin Tseng, Chieh-Kai Chan, Hsiang-Ying Lee, Chien-Ting Pan, Kang-Yung Peng, Shuo-Meng Wang, Kuo-How Huang, Yao-Chou Tsai, Vin-Cent Wu, Jeff S Chueh, and TAIPAI Study Group.
• Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
• J Formos Med Assoc. 2024 Mar 1; 123 Suppl 2: S125S134S125-S134.

AbstractPrimary aldosteronism (PA) is the most common cause of secondary hypertension and one of the few medical diseases that can be cured by surgery. Excessive aldosterone secretion is highly associated with cardiovascular complications. Many studies have shown that patients with unilateral PA treated with surgery have better survival, cardiovascular, clinical, and biochemical outcomes than those who receive medical treatment. Consequently, laparoscopic adrenalectomy is the gold standard for treating unilateral PA. Surgical methods should be individualized according to the patient's tumor size, body shape, surgical history, wound considerations, and surgeon's experience. Surgery can be performed through a transperitoneal or retroperitoneal approach, and via a single-port or multi-port laparoscopic approach. However, total or partial adrenalectomy remains controversial in treating unilateral PA. Partial excision will not completely eradicate the disease and is prone to recurrence. Mineralocorticoid receptor antagonists should be considered for patients with bilateral PA or patients who cannot undergo surgery. There are also emerging alternative interventions, including radiofrequency ablation and transarterial adrenal ablation, for which data on long-term outcomes are currently lacking. The Task Force of Taiwan Society of Aldosteronism developed these clinical practice guidelines with the aim of providing medical professionals with more updated information on the treatment of PA and improving the quality of care.Copyright © 2023. Published by Elsevier B.V.

15 keywords...

hide…